Alectinib for ALK-positive cancers in teens and adults
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether alectinib can treat ALK-positive cancers in adults, teenagers, and children. It focuses on people whose cancer testing shows an ALK change, and who can start oral treatment and have a new tissue sample.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be confirmed as “ALK-positive” on validated genetic testing (next-generation sequencing).
- You must be able and willing to have a fresh tissue biopsy for the study (with some blood/bone-marrow options for some blood cancers).
- If you can become pregnant: you must have a negative pregnancy test and use very effective birth control starting before treatment, during treatment, and for 3 months after the last dose.
- If you are male: you must not father children during treatment and for 3 months after; you must use barrier contraception (and/or ensure your partner uses very effective contraception).
- You must be able to take the medicine by mouth (swallowing/tolerating pills) and not have major stomach/intestine problems that affect absorption.
- You must have no major heart problems or recent stroke/heart attack, and no prior organ transplant.
- You must not have lung inflammation/scarring (interstitial lung disease/pneumonitis) or a history of it that hasn’t fully resolved.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two oral targeted drugs—alectinib and duvelisib—for people whose ALK-positive anaplastic large cell lymphoma has come back or not responded after at least one prior chemotherapy. The goal is to see if this combination can help control the cancer.
This early-phase trial studies how alectinib (an ALK-blocking medicine) moves through the body and how it’s tolerated in people with advanced non-small cell lung cancer (NSCLC) that has an ALK rearrangement. You may be considered if you have ALK-positive, recurrent or advanced disease and have already had specific prior treatments.
This study looks at how well alectinib works when given after surgery to people with early-stage ALK-positive non-small cell lung cancer. It aims to understand real-world outcomes for patients who take this targeted therapy as their first treatment after surgery.
This study tests two targeted pills, crizotinib and alectinib, for people with advanced bone cancer that has a specific gene change called ALK. These medicines block the ALK protein, which may help shrink or slow the cancer if standard treatments have stopped working.
This trial tests combining the targeted pill alectinib with chemotherapy before the main treatment for stage III ALK-positive lung cancer that can't be removed surgically. The goal is to see if this combo shrinks the tumor and improves outcomes.
This trial tests giving alectinib first, then adding targeted radiation to remaining spots of cancer in people with ALK-rearranged advanced non-small cell lung cancer. It aims to control the cancer after an initial response and help keep disease from progressing.
Hear when a new Lymphoproliferative Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.